Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
相关临床试验
4
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
50.0%
已完成
1
25.0%
招募中
1
25.0%
暂无批准数据
- Generate Biomedicines, backed by Flagship Pioneering, is seeking to raise up to $425 million in its U.S. IPO with a target valuation of $2.17 billion. - The AI-powered drug discovery company uses artificial intelligence to replace traditional trial-and-error methods and create novel protein-based therapeutics focused on immunology and oncology. - The company's lead candidate GB-0895 for severe asthma treatment is currently in late-stage trials, with full enrollment expected by the first half of 2028. - The IPO comes amid a resurgent biotech market in 2026, though investors remain cautious about AI drug discovery platforms as no fully AI-discovered drug has achieved FDA approval yet.
- King Abdullah International Medical Research Center and Flagship Pioneering announced a strategic partnership to conduct early-phase clinical trials of novel genetic disease therapies in Saudi Arabia. - The collaboration will initially focus on three Phase 1 programs and one Phase 2 program from Flagship-founded companies targeting genetic diseases with high unmet medical need. - Saudi investors will commit $70 million to participating U.S.-based companies as part of the partnership framework. - The agreement aims to establish Saudi Arabia as a leader in innovative clinical trials while advancing American biotechnology innovation globally.
- Generate Biomedicines has initiated two global Phase 3 clinical trials (SOLAIRIA-1 and SOLAIRIA-2) for GB-0895, an AI-engineered anti-TSLP monoclonal antibody designed to treat severe asthma with biannual dosing. - The trials will enroll approximately 1,600 patients with severe asthma that remains uncontrolled on existing therapies across North America, Europe, Latin America, and Asia Pacific regions. - Phase 1 trial results demonstrated favorable tolerance and dose-proportional pharmacokinetics, supporting the extended six-month dosing interval strategy for this ultra-high affinity TSLP-targeting antibody. - GB-0895 aims to reduce asthma exacerbations over 52 weeks by targeting thymic stromal lymphopoietin (TSLP), a key inflammation driver in severe asthma.
- IQVIA and Flagship Pioneering announced a strategic collaboration in August 2025 to accelerate breakthrough life sciences companies using AI-powered analytics and clinical trial expertise. - The partnership focuses on three core areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence for Flagship's 40+ biotech portfolio companies. - IQVIA's deployment of over 50 NVIDIA-built AI agents trained on 1.2 billion health records aims to reduce patient recruitment bottlenecks and accelerate clinical trial timelines. - The collaboration leverages Flagship's $14 billion in assets under management and IQVIA's $32.1 billion R&D backlog to enhance commercial viability of emerging biotech ventures.
